Atlantic Sapphire ASA
ASA.OL
Oslo Stock Exchange1.05
NOK
-0.20
- -
Atlantic Sapphire ASA
ASA.OL
(Oslo Stock Exchange)
Recent
price
1.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Atlantic Sapphire ASA (ASA.OL) is a Norway-based aquaculture company that specializes in land-based production of Atlantic salmon using its proprietary Bluehouse technology, which enables controlled, sustainable farming without ocean pens or marine-derived antibiotics, hormones, or parasites. Founded in 2010 and headquartered in Vikebukt, Norway, with principal operations including the Miami Bluehouse facility in Homestead, Florida, USA, and a facility in Denmark, the company produces premium Bluehouse salmon for fresh distribution primarily across North America; it offers whole fresh salmon, fillets, and value-added products such as portions and smoked salmon, emphasizing local farm-to-fork supply chains that minimize carbon footprints by avoiding air transport. Atlantic Sapphire serves retailers, foodservice providers, and wholesalers targeting environmentally conscious consumers seeking sustainable, high-quality seafood alternatives to traditional sea-farmed salmon. In a key recent development, the company entered a short-term lease agreement in early 2025 for its Danish facility with Maiken Foods AS, which includes an option for Maiken to purchase the site for its own land-based salmon pilot operations; it also continues operational enhancements at its Florida facility, including system overhauls completed on multiple units by mid-2025, insourcing of fillet production, record-low mortality rates, and plans for a $31-35 million convertible loan to support Phase 1 breakeven and Phase 2 expansion targeting 25,000 tons annual harvest capacity. These initiatives reflect ongoing strategic shifts toward improved biological performance, cost efficiencies, and financial stability following revenue growth to $21.5 million in H1 2025.